Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Primary objectives:
To determine the maximum tolerated doses (MTDs) of daily lenalidomide and docetaxel given
every three weeks and prednisone, as combination therapy to subjects with androgen
independent prostate cancer
To evaluate the safety profile of the combination of daily lenalidomide and every three week
docetaxel and prednisone when given to subjects with androgen independent prostate cancer
Secondary objective:
To explore the anti-tumor activity of the combination of daily lenalidomide and every 3 week
docetaxel and prednisone when given to subjects with androgen independent prostate cancer.